Rozprawy doktorskie na temat „Anti-cancer”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych rozpraw doktorskich naukowych na temat „Anti-cancer”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj rozprawy doktorskie z różnych dziedzin i twórz odpowiednie bibliografie.
Wheate, Nial Joseph Chemistry Australian Defence Force Academy UNSW. "Platinum anti-cancer complexes". Awarded by:University of New South Wales - Australian Defence Force Academy. School of Chemistry, 2001. http://handle.unsw.edu.au/1959.4/38704.
Pełny tekst źródłaBugarcic, Tijana. "Ruthenium arene anti-cancer complexes". Thesis, University of Edinburgh, 2008. http://hdl.handle.net/1842/13265.
Pełny tekst źródłaKuh, Hyo-Jeong. "Target site pharmacokinetics of anti-AIDS and anti-cancer agents /". The Ohio State University, 1997. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487943341527965.
Pełny tekst źródłaLau, Kelvin Kar Wing. "Vascular targeting of anti-cancer therapy". Thesis, University of Oxford, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.311869.
Pełny tekst źródłaCao, Siyu. "Designer bacteria as anti-cancer agents". Thesis, Griffith University, 2013. http://hdl.handle.net/10072/366498.
Pełny tekst źródłaThesis (PhD Doctorate)
Doctor of Philosophy (PhD)
School of Medical Science
Griffith Health
Full Text
Lyu, Jun Fang. "Discovery of cholesterol trafficking inhibitors as novel anti-angiogenic and anti-cancer agents". Thesis, University of Macau, 2018. http://umaclib3.umac.mo/record=b3953967.
Pełny tekst źródłaDeng, Zhao. "Anti-microbial and Anti-cancer activity of Traditional Chinese Medicine extracts". Thesis, Griffith University, 2020. http://hdl.handle.net/10072/401446.
Pełny tekst źródłaThesis (Masters)
Master of Science (MSc)
School of Environment and Science
Science, Environment, Engineering and Technology
Full Text
Qi, Ji. "Cane Toad Skin Extracts as Anti-Inflammatory and Anti-Cancer Agents". Thesis, Griffith University, 2016. http://hdl.handle.net/10072/365729.
Pełny tekst źródłaThesis (PhD Doctorate)
Doctor of Philosophy (PhD)
School of Medical Science
Griffith Health
Full Text
Wu, Na. "Identification of anti-resorptive and anti-cancer activities of epigenetic inhibitors". Thesis, University of Oxford, 2017. http://ora.ox.ac.uk/objects/uuid:9ae1e4e5-32b2-40e7-8249-5983d3e1bd6e.
Pełny tekst źródłaTrapika, I. Gusti Made Gde Surya Chandra. "Anti-Cancer Activity of Dendrobium chrysotoxum in human prostate cancer cells". Thesis, The University of Sydney, 2020. https://hdl.handle.net/2123/22501.
Pełny tekst źródłaLau, Kai Chi. "Quantum chemical studies of anti-cancer complexes /". Zürich : ETH, 2007. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=17547.
Pełny tekst źródłaLam, Fong Ki. "Discovery and evaluation of anti-cancer agents". Thesis, University of Nottingham, 2010. http://eprints.nottingham.ac.uk/11242/.
Pełny tekst źródłaDavison, Zoe. "Transcutaneous delivery of anti-breast cancer agents". Thesis, Cardiff University, 2008. http://orca.cf.ac.uk/54343/.
Pełny tekst źródłaBoys, Sarah K. "Tyrosine derivatives and their anti-cancer applications". Thesis, University of Edinburgh, 2012. http://hdl.handle.net/1842/6243.
Pełny tekst źródłaInman, Martyn William. "Catalytic processes in anti-cancer drug discovery". Thesis, University of Leeds, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.493304.
Pełny tekst źródłaDyer, Jolon Matthew. "Diels-Alder approaches to anti-cancer prodrugs". Thesis, University of Canterbury. Chemistry, 1998. http://hdl.handle.net/10092/6781.
Pełny tekst źródłaKärkkäinen, Tiina Sinikka. "Synthesis of glycopeptide-based anti-cancer vaccines". Thesis, University of East Anglia, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.273509.
Pełny tekst źródłaCooper, Margaret S. "Anti-cancer peptides containing modified tyrosine residues". Thesis, University of Nottingham, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.246193.
Pełny tekst źródłaSoldevila, Barreda Joan Josep. "Design of catalytic organometallic anti-cancer drugs". Thesis, University of Warwick, 2014. http://wrap.warwick.ac.uk/63808/.
Pełny tekst źródłaBennett, Ailsa. "Exploiting mitosis to improve anti-cancer strategies". Thesis, University of Manchester, 2017. https://www.research.manchester.ac.uk/portal/en/theses/exploiting-mitosis-to-improve-anticancer-strategies(b29182a1-2f37-47cb-8dc5-cbef76786dd2).html.
Pełny tekst źródłaBire, Christophe. "Données récentes sur la vaccination anti-cancer". Paris 5, 1994. http://www.theses.fr/1994PA05P043.
Pełny tekst źródłaOliva, Francisco. "The Anti-cancer Properties of Podophyllotoxin Analogues". Youngstown State University / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=ysu1579197212456721.
Pełny tekst źródłaRichardson, Monica Eilertsen. "Heterocyclic NO-donors as anti-cancer agents". Thesis, Keele University, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.699674.
Pełny tekst źródłaRan, Yingqing. "Applications of liposomes on anti-cancer agents". Diss., The University of Arizona, 2004. http://hdl.handle.net/10150/290047.
Pełny tekst źródłaWong, Suk-yu. "Study of anti-cancer and anti-viral activities of lanthanide and vanadium complexes". View the Table of Contents & Abstract, 2006. http://sunzi.lib.hku.hk/hkuto/record/B36584599.
Pełny tekst źródłaWong, Suk-yu, i 黃淑如. "Study of anti-cancer and anti-viral activities of lanthanide and vanadium complexes". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2006. http://hub.hku.hk/bib/B37674547.
Pełny tekst źródłaMelo, Candice Soares de. "Anti-cancer and anti-malarial 4-aminoquinoline derivatives : synthesis and solid-state investigations". Master's thesis, University of Cape Town, 2006. http://hdl.handle.net/11427/6334.
Pełny tekst źródłaThe work presented in this thesis is two-fold: (i) development of single agents that provide inhibition of both the growth of malaria parasites and of tumour cells in vitro, and (ii) inclusion of these potential novel inhibitors in cyclodextrin host molecules in an attempt to render these dual drugs water-soluble. Of all the current clinically established antimalarials, the 4-aminoquinolines haveproven to be the most significant and efficacious for the treatment and prophylaxis of malaria. However, their efficacy has decreased by the spread of drug resistant strains of the causative agent Plasmodium Jalciparum. Future research into 4-aminoquinoline derivatives as antimalarial agents is still warranted and justified on the basis of several considerations. The quinoline moiety has also been shown to be a substructure in multi-drug resistance reversal agents against certain cancer cell lines and antitumour agents which have demonstrated the ability to act as differentiation-inducing agents. The strategy employed for this project was to hybridize chalcone moieties and their Mannich base derivatives with the 4-aminoquinoline moiety. This dual drug concept uses the basic structure of the chalcone scaffold, which has a wide range of known antimalarial and anticancer activities, and is hybridised with the 4-aminoquinoline moiety, in order to exert maximal biological activity and overcome or prevent drug resistance. Structural variation on the aromatic rings of the chalcone scaffold allowed preliminary structure-activity relationship studies to be undertaken.
Studebaker, Adam Wade. "Targteing uracil exclusion mechanisms for development of anti-viral and anti-cancer therapies". The Ohio State University, 2003. http://rave.ohiolink.edu/etdc/view?acc_num=osu1056034774.
Pełny tekst źródłaStudebaker, Adam W. "Targeting uracil exclusion mechanisms for development of anti-viral and anti-cancer therapies". Connect to this title online, 2003. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1056034774.
Pełny tekst źródłaTitle from first page of PDF file. Document formatted into pages; contains xiii, 210 p.; also includes graphics (some col.). Includes bibliographical references (p. 174-210). Available online via OhioLINK's ETD Center
O'Riley, Hannah Adele. "Mechanisms of the Anti-Metastatic and Cytotoxic Properties of Ruthenium Anti-Cancer Drugs". Thesis, The University of Sydney, 2015. http://hdl.handle.net/2123/13881.
Pełny tekst źródłaButler, Gregory James. "Non-steroidal anti-inflammatory drugs and skin cancer /". [St. Lucia, Qld.], 2005. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe19122.pdf.
Pełny tekst źródłaBulmer, J. Todd. "Cellular responses to the anti-cancer drug, cisplatin /". *McMaster only, 2001.
Znajdź pełny tekst źródłaZong, Jingyi. "The development of anti-cancer drug delivery systems". Thesis, Durham University, 2016. http://etheses.dur.ac.uk/11927/.
Pełny tekst źródłaOleschuk, Curtis. "Structure-activity studies of bioreductive anti-cancer agents". Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk2/tape17/PQDD_0002/MQ32204.pdf.
Pełny tekst źródłaFaragalla, Jane Eliza. "Development of isoflavonoid-derived anti-prostatic cancer agents". Access electronically, 2005. http://www.library.uow.edu.au/adt-NWU/public/adt-NWU20060516.121728/index.html.
Pełny tekst źródłaHill, Richard James. "Immunocompetent tumour model for anti-cancer adenovirus treatment". Thesis, Imperial College London, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.414451.
Pełny tekst źródłaHagan, Damien James. "The synthesis of novel anti-cancer acridine derivatives". Thesis, University of Nottingham, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.284428.
Pełny tekst źródłaCook, Andrew James. "Metal catalysed approaches to novel anti-cancer agents". Thesis, University of Leeds, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.411359.
Pełny tekst źródłaManoharan, Gunasekar. "Anti-cancer effects of Momordica charantia in-vitro". Thesis, University of Central Lancashire, 2011. http://clok.uclan.ac.uk/2822/.
Pełny tekst źródłaMehta, Shaveta. "Biomarkers of anti-angiogenic therapy in breast cancer". Thesis, University of Oxford, 2014. http://ora.ox.ac.uk/objects/uuid:8b3869e3-fd60-450c-b165-0fe773681613.
Pełny tekst źródłaGhandhi, Laura Hester Dena. "Cobalt picolinamide complexes as potential anti-cancer agents". Thesis, University of Leeds, 2017. http://etheses.whiterose.ac.uk/17618/.
Pełny tekst źródłaChuang, Hsiao-Ching. "Mechanistic Validation of Potential Anti-Breast Cancer Therapeutics". The Ohio State University, 2012. http://rave.ohiolink.edu/etdc/view?acc_num=osu1338213365.
Pełny tekst źródłaSindi, Shaimaa Hesham. "Guanidine- Based HDAC-Inhibitors as Anti-Cancer Agents". University of Toledo / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=toledo1564676186975875.
Pełny tekst źródłaShahi, Thakuri Pradip. "MODELING ANTI-CANCER DRUG RESISTANCE USING TUMOR SPHEROIDS". University of Akron / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=akron1574725861735168.
Pełny tekst źródłaLaw, Ka Man. "Anti-cancer effect of ginsenosides on nasopharyngeal carcinoma". HKBU Institutional Repository, 2012. https://repository.hkbu.edu.hk/etd_ra/1383.
Pełny tekst źródłaJagdev, Satinder P. K. "Anti-tumour effects of bisphosphonates in breast cancer". Thesis, University of Sheffield, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.427201.
Pełny tekst źródłaBroughton, Laura J. "Characterisation of duramycin as an anti-cancer agent". Thesis, University of Hull, 2016. http://hydra.hull.ac.uk/resources/hull:15303.
Pełny tekst źródłaShehata, Sara <1993>. "Synthesis of Anti-Metastatic Agent for Cancer Theraphy". Master's Degree Thesis, Università Ca' Foscari Venezia, 2018. http://hdl.handle.net/10579/13854.
Pełny tekst źródłaGuardia, Valenzuela Cristina 1990. "Cancer-associated fibroblasts and response to anti-HER2 monoclonal antibodies in breast cancer". Doctoral thesis, Universitat Pompeu Fabra, 2019. http://hdl.handle.net/10803/668327.
Pełny tekst źródłaHER2-positive breast cancer (BC) is an aggressive subtype of this disease. The development of anti-HER2 targeted therapies, particularly the monoclonal antibody (Mab) trastuzumab, significantly improved its otherwise poor prognosis. More recently, another Mab called pertuzumab, has further improved the efficacy of trastuzumab, yet no all patients benefit from the combination of the two Mabs. A proportion of HER2-breast cancer patients will not benefit from anti-HER2 agents, and will ultimately die as a consequence of innate or acquired drug resistance mechanisms. Tumours consist not only of heterogeneous populations of cancer cells, but also of the tumour microenvironment (TME). In recent years, increasing evidence has shown that cancer-associated fibroblasts (CAFs; an abundant stromal cell population within the TME), directly support tumorigenesis and promote therapy resistance. However, at the beginning of this PhD study, there was little published work on the role of CAFs on anti-HER2 targeted therapy resistance. The work presented in this doctoral thesis supported a role of CAFs in tumour resistance to anti-HER2 targeted therapies in HER2+ breast cancer through paracrine secretion of soluble molecules that ultimately will promote breast cancer survival and therapy resistance.
Verghese, Jenson. "Investigations of Novel Mechanisms of Action for Anti-Bacterial and Anti-Cancer Agent Development". VCU Scholars Compass, 2014. http://scholarscompass.vcu.edu/etd/611.
Pełny tekst źródła